Theresa Medina, MD
Medical Oncology · Aurora, CONPI 1669645867
Payments from drug & device makers
Across 609 payments — averaging $11,513 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2.4M
- E.r. Squibb & Sons, L.L.C.$1.3M
- Regeneron$832K
- Hoffmann-la Roche Limited$562K
- Modernatx, Inc.$487K
- Seagen Inc.$354K
- plus $1.1M from 13 others
Across 17 payments — averaging $343.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$6K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 76 | $2,420,015 |
| E.r. Squibb & Sons, L.L.C. | 35 | $1,283,545 |
| Regeneron | 120 | $831,796 |
| Hoffmann-la Roche Limited | 26 | $561,940 |
| Modernatx, Inc. | 61 | $486,598 |
| Seagen Inc. | 88 | $354,367 |
| Genentech, Inc. | 63 | $278,119 |
| Iovance Biotherapeutics, Inc. | 21 | $218,677 |
| Trisalus Life Sciences, Inc. | 38 | $179,350 |
| Dynavax Technologies Corporation | 18 | $118,971 |
| Pfizer | 38 | $111,045 |
| Amgen | 1 | $104,118 |
| GSK | 8 | $22,722 |
| Incyte Corporation | 4 | $14,421 |
| Ares Trading SA | 4 | $10,308 |
| Novartis | 2 | $9,629 |
| Day One Biopharmaceuticals | 4 | $5,632 |
| Immunocore Limited | 1 | $295 |
| Bristol Myers Squibb | 1 | $18 |
How this compares
$7,011,564 in reported general payments places this provider in the 95th percentile of 96 medical oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Aurora
- Karl LewisAurora$12.4M
- Christopher LieuAurora$8M
- David CamidgeAurora$7.3M
- Wells MessersmithAurora$6.3M
- Antonio JimenoAurora$5.6M
- Elizabeth KesslerAurora$5.1M
- Sarah DavisAurora$3.9M
- Sunnie KimAurora$3.9M
- Peter KabosAurora$3.5M
- Robert LentzAurora$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.